Florida Cancer Specialists Drives Two FDA Approvals for Breast and Pancreatic Cancer Therapies
Event summary
- Florida Cancer Specialists (FCS) contributed to FDA approvals of camizestrant for HR-positive, HER2-negative breast cancer and daraxonrasib for metastatic pancreatic cancer.
- Camizestrant's Phase 1 trial began at FCS's Sarasota Drug Development Unit in 2019, with Phase 3 results showing nearly double the progression-free survival vs. control.
- Daraxonrasib's pivotal trial showed median overall survival of 13.2 months vs. 6.7 months with standard chemotherapy.
- FCS has participated in the majority of new cancer drug approvals in the U.S. over the past decade.
The big picture
Florida Cancer Specialists' involvement in these FDA approvals underscores its position as a leader in community-based oncology research. The approvals highlight the growing importance of targeted therapies in treating resistant cancers and the critical role of early-phase clinical trials in accelerating drug development. FCS's ability to consistently contribute to major oncology advancements positions it as a key player in the evolving landscape of cancer care.
What we're watching
- Pipeline Expansion
- Whether FCS can sustain its role in developing new cancer therapies through ongoing studies in breast, pancreatic, and other tumor types.
- Clinical Trial Access
- The pace at which FCS expands access to innovative clinical trials across its nearly 30 locations statewide.
- Strategic Partnerships
- How FCS's collaborations with Sarah Cannon Research Institute and Paradigm, Inc. will influence future drug development and approvals.
Related topics
